Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
UK MHRA began rolling review of Moderna’s mRNA COVID-19 vaccine
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Additional COVID-19 related genes ï¾– both helpful and harmful ï¾– revealed in massive screen
On Oct. 27, 2020, researchers at Yale University and the Broad Institute of MIT and Harvard screened hundred…
Moderna announced supply agreement with Qatar for mRNA vaccine against COVID-19
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
RNA ‘ticker tape’ records gene activity over time
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
DARPA awarded Moderna $56 Million to enable small-scale, rapid mobile manufacturing of vaccines and therapeutics
On Oct. 8, 2020, Moderna announced an agreement for a commitment of up to $56 million from the…
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services announced funding of a patch that…
Broad and Brigham and Women’s Hospital launched COVID-19 surveillance study
On Oct. 6, 2020, clinicians and researchers from Brigham and Women’s Hospital, the Broad Institute of MIT and…
Johnson & Johnson completed acquisition of Momenta Pharmaceuticals for $65 billion
On Oct. 1, 2020, Johnson & Johnson announced it had successfully completed its acquisition of Momenta Pharmaceuticals, a…
Moderna announced publication in The NEJM of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1…
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
Elevated levels of a blood clotting factor linked to worse outcomes in severe COVID-19
On Sept. 9, 2020, Harvard Medical School investigators at Massachusetts General Hospital reported that patients hospitalized with severe…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Biopharma leaders united to stand with science
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
Broad Institute provided COVID-19 screening for students, faculty and staff at more than 100 colleges and universities
On Sept. 2, 2020, Broad Institute of MIT and Harvard announced it had partnered with 108 public and…
Moderna confirmed discussions with the MHLW to supply Japan with 40 million doses of mRNA vaccine against COVID-19
On Aug. 28, 2020, Moderna confirmed that the Company was engaged in discussions with the Ministry of Health,…
Rapid diagnostic detected Lassa and Ebola in real-time
On Aug. 26, 2020, researchers announced an inexpensive, sensitive, CRISPR-based tests diagnose two deadly viruses in settings with…
How SARS-CoV-2 spread across greater Boston during pandemic’s first wave
On Aug. 25, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, the Massachusetts…
Genomic analysis revealed many animal species may be vulnerable to SARS-CoV-2 infection
On Aug. 24, 2020, humans are not the only species facing a potential threat from SARS-CoV-2, the novel…
Evidence suggested children could play a larger role in community spread of COVID-19
On Aug. 20, 2020, in the most comprehensive study of COVID-19 pediatric patients to date, Harvard Medical School…
Johnson & Johnson acquired Momenta Pharmaceuticals for $65 billion
On Aug. 19, 2020, Johnson & Johnson announced an agreement to acquire Momenta Pharmaceuticals, a company that discovers…
Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
Yale researchers part of new NSF-funded quantum center
On Aug. 4, 2020, Yale University announced it was among the core partners of the new Center for…
Moderna announced publication in the NEJM of non-human primate preclinical viral challenge study of its mRNA vaccine against COVID-19
On Jul. 28, 2020, Moderna announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published…
Phase 3 clinical trial of investigational vaccine for COVID-19 began
On Jul. 27, 2020, the National Institutes of Health (NIH) announced that a phase 3 clinical trial designed…
Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…